Question 1 - SIU Kidney Cancer Quiz

Level: Easy

QUESTION 1:
Which of the following drugs is a programmed death-1 (PD-1) inhibitor?

a) Durvalumab b) Nivolumab c) Tremelimumab d) Avelumab e) Atezolizumab

Correct

Incorrect, the correct answer is b

Submit

Level: Easy

QUESTION 2:
Several immune checkpoint inhibitor adjuvant trials have recently been performed in kidney cancer. Which of the following drugs is approved for adjuvant use following resection of renal cancer with a high risk of recurrence?

a) Nivolumab plus ipilimumab b) Pembrolizumab c) Atezolizumab d) Nivolumab e) Durvalumab plus tremelimumab

Correct

Incorrect, the correct answer is b

Submit

Level: Easy

QUESTION 3:
Which of the following statements regarding cytoreductive nephrectomy (CN) in the era of immune checkpoint inhibitor combination therapy is TRUE?

a) Deferred CN following immune checkpoint inhibitor therapy is supported by randomized controlled trials. b) Inflammatory reactions following immune checkpoint inhibitor therapy facilitate surgical resection. c) Patients with oligometastatic disease do not benefit from CN. d) Retrospective data suggest that patients with complete response at metastatic sites can gain durable complete remission by deferred CN e) To improve response to immunotherapy, CN should be offered upfront.

Correct

Incorrect, the correct answer is d

Submit

Level: Easy

QUESTION 4:
Which statement about adverse events reported in adjuvant renal cancer trials with immune checkpoint inhibitors is TRUE?

a) Adjuvant atezolizumab had the highest frequency of treatment-related adverse events compared to other adjuvant immune checkpoint inhibitors. b) All-cause adverse events of any grade led to discontinuation of adjuvant nivolumab plus ipilimumab in 32% of treated patients. c) The most common adverse event with adjuvant pembrolizumab was hand-foot syndrome. d) There were no deaths attributed to treatment with adjuvant nivolumab plus ipilimumab. e) Serious adverse events were not observed with adjuvant atezolizumab.

Correct

Incorrect, the correct answer is b

Submit

Level: Easy

QUESTION 5:
Which of the following is not a subtype entity in kidney cancer?

a) Papillary b) Clear cell c) Sarcomatoid d) Collecting duct carcinoma e) Chromophobe

Correct

Incorrect, the correct answer is c

Submit

Thanks for helping me out. You’re all set to move forward.

Continue

Level: Easy

QUESTION 1:Which of the following drugs is a programmed death-1 (PD-1) inhibitor?

Level: Easy

QUESTION 2:Several immune checkpoint inhibitor adjuvant trials have recently been performed in kidney cancer. Which of the following drugs is approved for adjuvant use following resection of renal cancer with a high risk of recurrence?

Level: Easy

QUESTION 3:Which of the following statements regarding cytoreductive nephrectomy (CN) in the era of immune checkpoint inhibitor combination therapy is TRUE?

Level: Easy

QUESTION 4:Which statement about adverse events reported in adjuvant renal cancer trials with immune checkpoint inhibitors is TRUE?

Level: Easy

QUESTION 5:Which of the following is not a subtype entity in kidney cancer?

QUESTION 1:
Which of the following drugs is a programmed death-1 (PD-1) inhibitor?

QUESTION 2:
Several immune checkpoint inhibitor adjuvant trials have recently been performed in kidney cancer. Which of the following drugs is approved for adjuvant use following resection of renal cancer with a high risk of recurrence?

QUESTION 3:
Which of the following statements regarding cytoreductive nephrectomy (CN) in the era of immune checkpoint inhibitor combination therapy is TRUE?

QUESTION 4:
Which statement about adverse events reported in adjuvant renal cancer trials with immune checkpoint inhibitors is TRUE?

QUESTION 5:
Which of the following is not a subtype entity in kidney cancer?